We are live on ! Find out more

Bruker

BRKR

Market cap $8.9B

58.41 USD

+2.48

4.43%

At close Updated Oct 21, 2:06 PM EDT

1 day

4.43%

5 days

6.26%

1 month

-5.15%

3 months

-3.34%

6 months

45.7%

Year to date

21.41%

1 year

50.62%

5 years

-25.38%

10 years

172.18%

About: Bruker Corp manufactures scientific instruments and diagnostic tests for customers in the life sciences, applied markets, pharmaceutical, and biotechnology industries. The company operates in segments, namely, Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies (BEST) . The company generates maximum revenue from the BSI CALID segment. Geographically, it derives the maximum of its revenue from United States.

Employees: 11,085

Healthcare Medical Devices

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 29.2%

Neutral 70.8%

Negative 0%

Bruker Announces Date and Time of Third Quarter 2026 Earnings Release and Webcast

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced it will report third quarter 2026 financial results before market opening on Wednesday, November 4, 2026. The Company will host a conference call and webcast at 8:30 a.m. Eastern Daylight Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q3 2026 Earnings Webcast” hyperlink in the “Events & Presentations” section. A.

Bruker Announces Date and Time of Third Quarter 2026 Earnings Release and Webcast

Zacks Investment Research

Bruker Gains 66.3% in a Year: What's Driving the Rally?

BRKR shares surge 66.3% in a year, fueled by strong demand in mass spectrometry and biopharma, despite restructuring challenges and currency headwinds.

Bruker Gains 66.3% in a Year: What's Driving the Rally?

Untargeted timsTOF Mass Spectrometry Enables Discovery and Mapping of Draft Atlas of the Human Plasma Proteome at Proteoform Resolution

BERLIN--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced a seminal bioRxiv preprint, describing a draft atlas of the human plasma proteome at isoform, or proteoform, resolution. The study was conducted by principal investigator Markus Ralser at Charité – Universitätsmedizin Berlin and collaborators. The preprint “A draft atlas of the human plasma proteome at isoform resolution” was posted on September 28, 2026 at https://doi.org/10.64898/2026.09.26.754256. By combining intact protei.

Untargeted timsTOF Mass Spectrometry Enables Discovery and Mapping of Draft Atlas of the Human Plasma Proteome at Proteoform Resolution

Zacks Investment Research

Why Bruker (BRKR) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

Why Bruker (BRKR) is a Top Momentum Stock for the Long-Term

Bruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology Research

SINGAPORE--(BUSINESS WIRE)---- $BRKR #BRKR--At the Human Proteome Organization World Congress 2026, Bruker Corporation (Nasdaq: BRKR) today announced unique new timsUltra AIP and timsOmni workflows for deeper protein-sequence coverage, targeted validation, mobility-resolved glycopeptide characterization, structural proteomics, and oligonucleotide analysis. Multi-enzyme dia-PASEF provides additional peptide information for investigations of isoforms and proteoforms, while ProteoScape workflows connect PASEF dis.

Bruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology Research

Bruker Sees AI-Fueled Semiconductor Demand, Targets Critical Q4 Revenue Rebound

Bruker NASDAQ: BRKR CFO Gerald Herman said the company's second-quarter results reflected stronger-than-expected organic order bookings and earnings per share, while revenue came in later than anticipated. He attributed the revenue timing primarily to a mixed demand environment and shipment timing, including semiconductor-metrology orders that are expected to shift into the fourth quarter.

Bruker Sees AI-Fueled Semiconductor Demand, Targets Critical Q4 Revenue Rebound

Bruker Corporation (BRKR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Bruker Corporation (BRKR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Bruker Corporation (BRKR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Bruker Receives Order for High-Field NMR Systems for Major Upgrade of Magnetic Resonance Research Infrastructure at UC Berkeley

BERKELEY, Calif.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced a multi-system order from the University of California, Berkeley for high-field Nuclear Magnetic Resonance (NMR) instrumentation at the Pines Magnetic Resonance Center. The investment will enhance access to next-generation NMR technologies, including 800 MHz–class instrumentation. These capabilities strengthen research in chemistry, materials science, structural biology, and related fields across UC Berkeley an.

Bruker Receives Order for High-Field NMR Systems for Major Upgrade of Magnetic Resonance Research Infrastructure at UC Berkeley

Bruker Corporation (BRKR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Bruker Corporation (BRKR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Bruker Corporation (BRKR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Bruker Corporation (BRKR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Bruker Corporation (BRKR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Bruker Corporation (BRKR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

See News Rankings

Price charts implemented using Lightweight Charts™